ESMO Immuno-Oncology Congress 2021
Trained immunity: a new promising oncology target?
In-depth understanding of immunological cellular mechanisms provides the basis to explore new ways to modulate the immune system for more effective treatment of cancer
Survival benefits of pembrolizumab plus chemotherapy are confirmed in East-Asian patients with advanced NSCLC
Immunotherapy plus chemotherapy as first-line treatment choice for advanced disease without oncogene mutations, irrespective of ethnicity and PD-L1 status
Immunotherapy: from initial scepticism to the heart of cancer treatment
The ESMO Award for Immuno-Oncology 2021 is given to Prof. Wolf H. Fridman, whose research has made significant contributions to unveiling the prognostic and predictive role of the tumour microenvironment
How much is enough with immunotherapy?
For the recipient of the ESMO Award for Immuno-Oncology 2020, Dr Jedd Wolchok, one of the biggest challenges in the field is knowing how and when to de-escalate immunotherapy